(Q36681145)

15 August 2017

1 reference

title

The design of inhibitors for medicinally relevant metalloproteins (English)

1 reference

15 August 2017

Seth M Cohen

3

0 references

author name string

Faith E Jacobsen

series ordinal

1

1 reference

PubMed ID

17163561

15 August 2017

Jana A Lewis

series ordinal

2

1 reference

15 August 2017

1 February 2007

1 reference

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

152-171

1 reference

15 August 2017

2

1 reference

Carbonic anhydrase. Purification and nature of the enzyme

15 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

Functional Polymorphism in the Regulatory Region of Gelatinase B Gene in Relation to Severity of Coronary Atherosclerosis

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FCMDC.200600204

21 January 2018

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

How matrix metalloproteinases regulate cell behavior

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure and function of matrix metalloproteinases and TIMPs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases: biologic activity and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

MMP induction and inhibition in myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Inflammatory cytokines and postmyocardial infarction remodeling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Role of matrix metalloproteinases in asthma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A bioinorganic perspective on matrix metalloproteinase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Alpha 2-macroglobulin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Design and therapeutic application of matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Quest for selectivity in inhibition of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Purification of human collagenases with a hydroxamic acid affinity column

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)]Cl x H2Sha, a model for a peroxidase-inhibitor complex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Effect of microbial siderophores on matrix metalloproteinase-2 activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Inhibition of matrix metalloproteinase-2 activity by siderophores of Pseudomonas species

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Succinylhydroxamic derivatives of alpha-amino acids as MMP inhibitors. Study of complex-formation equilibria with Cu2+, Ni2+ and Zn2+.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Recent advances in MMP inhibitor design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Captopril: pharmacology, metabolism and disposition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Crystal structures of matrilysin-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

4-alkylidene-azetidin-2-ones: novel inhibitors of leukocyte elastase and gelatinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Squaric acid-based peptidic inhibitors of matrix metalloprotease-1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Zinc sensing for cellular application

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Illuminating zinc in biological systems

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A new role for old ligands: discerning chelators for zinc metalloproteinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Antimetastatic activity of a novel mechanism-based gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Ageladine A: an antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structural Differences of Matrix Metalloproteinases with Potential Implications for Inhibitor Selectivity Examined by the GRID/CPCA Approach

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A practical approach to docking of zinc metalloproteinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Virtual screening against metalloenzymes for inhibitors and substrates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Discovering high-affinity ligands for proteins: SAR by NMR

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Using model complexes to augment and advance metalloproteinase inhibitor design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Potent, selective pyrone-based inhibitors of stromelysin-1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Carbonic anhydrase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, andN-Hydroxysulfonamides Inhibit Both These Zinc Enzymes1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Applications of carbonic anhydrase inhibitors and activators in therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Screening derivatized peptide libraries for tight binding inhibitors to carbonic anhydrase II by electrospray ionization-mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Recent progress in the development of assays suited for histone deacetylase inhibitor screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Deacetylase enzymes: biological functions and the use of small-molecule inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Histone deacetylase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Cardiac hypertrophy: the good, the bad, and the ugly

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Histone Deacetylase Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A role for histone deacetylase activity in HDAC1-mediated transcriptional repression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Histone deacetylase inhibitors: multifunctional anticancer agents.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The medicinal chemistry of botulinum, ricin and anthrax toxins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200600204

1 reference

7 January 2021

Anthrax lethal toxin: a weapon of multisystem destruction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Asymmetric hydrogenation of N-sulfonylated-alpha-dehydroamino acids: toward the synthesis of an anthrax lethal factor inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Screening inhibitors of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Identification of small molecule inhibitors of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Efficient synthetic inhibitors of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Dual effect of synthetic aminoglycosides: antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Botulinum Toxin as a Biological Weapon: Medical and Public Health Management

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Light Chain of Botulinum Neurotoxin Serotype A: Structural Resolution of a Catalytic Intermediate†,‡

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Quorum sensing: an emerging target for antibacterial chemotherapy?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Quorum Sensing in Bacteria

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Bacterial cell-to-cell signaling in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Interspecies communication in bacteria

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Synthesis of LuxS inhibitors targeting bacterial cell-cell communication

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Design and synthesis of substrate and intermediate analogue inhibitors of S-ribosylhomocysteinase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Characterization of a human peptide deformylase: implications for antibacterial drug design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600204

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600204

1 reference

15 August 2017

1 reference

PubMed ID

17163561